Haymerle G, Kadletz L, Wiebringhaus R, Golabi B, Mildner M, Thurnher D, Heiduschka G
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Clin Otolaryngol. 2017 Dec;42(6):1181-1186. doi: 10.1111/coa.12845. Epub 2017 Mar 13.
Despite the excellent overall survival of 92%-97% in early glottic cancer, recurrence rates of 13%-20% have not improved in the last decades. The engulfment and cell motility protein 3 (ELMO3) have been described as prognostic marker in patients with lung cancer. The aim of this study was to investigate the expression of ELMO3 in early laryngeal cancer patients treated with TLM and to evaluate its prognostic significance on clinical outcome.
DESIGN, SETTING AND PARTICIPANT: Forty-eight patients with glottic carcinoma (T1N0M0) that underwent primary treatment with TLM between 1994 and 2012 were analysed. ELMO3 expression of the tumour was assessed using immunohistochemistry and correlated with clinical data.
Overall survival, disease-specific survival (DSS) and disease-free survival (DFS) rates RESULTS: Positive ELMO3 expression was found in 23% of the patients and was correlated with poor DSS and DFS (P<.05).
This is the first study to show a prognostic effect of positive ELMO3 expression in early glottic carcinoma patients.
尽管早期声门癌的总体生存率高达92%-97%，但在过去几十年中，其13%-20%的复发率并未得到改善。吞噬与细胞运动蛋白3（ELMO3）已被描述为肺癌患者的预后标志物。本研究的目的是调查ELMO3在接受TLM治疗的早期喉癌患者中的表达情况，并评估其对临床结局的预后意义。
设计、背景与参与者：分析了1994年至2012年间接受TLM初次治疗的48例声门癌患者（T1N0M0）。采用免疫组织化学方法评估肿瘤的ELMO3表达，并将其与临床数据相关联。
总生存率、疾病特异性生存率（DSS）和无病生存率（DFS）
23%的患者ELMO3表达呈阳性，且与较差的DSS和DFS相关（P<0.05）。
这是第一项显示ELMO3阳性表达对早期声门癌患者有预后影响的研究。
